Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Raw Materials (2022 - 2025)

Historic Raw Materials for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $6.1 million.

  • Arcutis Biotherapeutics' Raw Materials rose 4962.09% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 4962.09%. This contributed to the annual value of $4.3 million for FY2024, which is 5678.83% down from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Raw Materials of $6.1 million as of Q3 2025, which was up 4962.09% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Raw Materials registered a high of $11.2 million during Q3 2023, and its lowest value of $3.5 million during Q3 2022.
  • Over the past 4 years, Arcutis Biotherapeutics' median Raw Materials value was $6.5 million (recorded in 2023), while the average stood at $6.8 million.
  • In the last 5 years, Arcutis Biotherapeutics' Raw Materials skyrocketed by 22064.13% in 2023 and then tumbled by 6349.11% in 2024.
  • Over the past 4 years, Arcutis Biotherapeutics' Raw Materials (Quarter) stood at $5.7 million in 2022, then soared by 75.84% to $10.0 million in 2023, then plummeted by 56.79% to $4.3 million in 2024, then surged by 42.28% to $6.1 million in 2025.
  • Its Raw Materials was $6.1 million in Q3 2025, compared to $6.7 million in Q2 2025 and $7.6 million in Q1 2025.